The Investment objective of the fund is to achieve long term growth by investing in a managed portfolio of equities investing mainly in the UK and fixed interest investments such as corporate bonds and gilts.
Name | % Net Assets |
---|---|
BP | 3.9% |
Royal Dutch Shell | 3.8% |
HSBC Hldgs | 3.2% |
GlaxoSmithKline | 3.0% |
Treasury 4.25% 12/2055 | 2.6% |
GlaxoSmithKline | 2.5% |
DBR 4.25 07/39 | 2.4% |
BG Group | 1.7% |
BHP Billiton | 1.4% |
AstraZeneca | 1.3% |
Key | % Net Assets |
---|---|
BP | 3.9% |
Royal Dutch Shell | 3.8% |
HSBC Hldgs | 3.2% |
GlaxoSmithKline | 3.0% |
Other | 86.1% |
Date | 21-Nov-2024 |
---|---|
NAV | 48.91p |
Currency | GBP |
Change | 0.030p |
% | 0.06% |
YTD change | 1.61p |
YTD % | 3.40% |
Fund Inception | 06/04/2005 |
---|---|
Fund Manager | Matthew Merritt |
TER | - |
Minimum Investment | |
---|---|
Initial | £3000 |
Additional | n/a |
Savings | £50 |
Charges | |
---|---|
Initial | n/a |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.01 |
Sharpe ratio | 0.07 |
You are here: research